Bujanos BI, Rivera MIM, Ramos JJ, Erhard RA

Language: Spanish
References: 18
Page: 54-58
PDF size: 166.35 Kb.

ABSTRACT

introduction. The widely use of highly active antiretroviral therapy (HAART) has currently reduced significantly HIV-related morbidity and mortality. However, other clinical problems mainly metabolic have emerged as glucose intolerance, insulin resistance, dyslipidemia and lipodystrophy.
objective. Comparison of metabolic profile (LDL cholesterol, HDL cholesterol, triglycerides, serum glucose) in patients with and without lipodystrophy on HAART.
methods. An observational, comparative study. The population is made up of patients with HIV infection with at least 6 months with HAART recruited from 3 centers specializing in HIV Monterrey (Hospital Universitario, ISSSTE and CAPASITS). The sample size of 45 subjects per group was calculated. A questionnaire on medical history and clinical variables was performed. Lipid profile and blood chemistry was performed.
results. LDL, HDL, Triglycerides, Glucose between the two groups of patients was compared. Ninety two subjects were included: 47 with lipodystrophy and subclassified into 3 types: Hypotrophic, hypertrophic and mixed, and 45 without lipodystrophy. The values of total cholesterol and triglycerides were statistically higher in the group of patients with lipodystrophy. No statistically significant difference was found in the values of the measured parameters between types of lipodystrophy.
conclusions. The Lipodystrophy in HIV-infected patients on HAART significantly associated with a greater degree of dyslipidemia that can determine increased risk of atherosclerosis and cardiovascular complications.

REFERENCES

1. Palella F, Delaney K, Moorman A, Loveless MO, Fuhrer J, Satten GA, et al. “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.” N Eng J Med 1998; 338: 853-860.

2. Sepkowitz KA. “AIDS-The first 20 years”. N Eng J Med 2001; 344: 1764-1772.

3. Carr A, Cooper D. “Adverse effects of antiretroviral therapy”. Lancet 2000; 356: 1423-1430.

4. Hirsch HH, Battegay M. “Lipodystrophy Syndrome by HAART in HIVInfected Patients: Manifestation, Mechanisms and Management”. Infection 2002; 30: 293-298.

5. Wanke CA. “Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome”. AIDS. 1999; 13:1287.

6. May MT,Sterne JA, Costagliola D, et al. “HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy; a collaborative analysis”. Lancet 2006; 368:451.

7. Carr A. “HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management”. AIDS 2003; 17 suppl 1:S141.

8. Carr A, Emery S, Law M, et al. “An objective case definition of lipodystrophy in HIV-infected adults: a case-control study”. Lancet 2003;361:726–735.

9. Wanke CA, Falutz J, Shevitz A, Phair JP, Kotler DP. “Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus”. Clin Infect Dis 2002; 34: 248-259.

10. Blanco F, García-Benayas T, Soriano V. “Síndrome de lipodistrofia asociado a la infección por el VIH (I). Características generales y etiopatogenia”. Rev Clin Esp 2002; 202: 27-31.

11. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. “A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors”. AIDS 1998; 12: F51-F58.

12. Brinkman K, Hofstede H. “Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral- therapyrelated lipodystrophy”. Lancet 1999; 354: 1112-1115.

13. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. „Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome”. J Clin Endocrinol Metab 1992; 74: 1045-1052.

14. Crum-Cianflone N, Tejidor R, Medina S, et al. “Obesity among patients with HIV: the latest epidemic”. AIDS Patient Care STDS 2008; 22:925.

15. Fauvel J, Bonnet E, Ruidavets JB, Ferrieres J, Toffoletti A, Massip P, et al. “An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/ low HDL lev els in treated HIV patients”. AIDS 2001; 15: 2397-2406.

16. Goujard C, Boufassab F, Deveau C, Laskri D, Meyerb L. “Incidence of clinical lipodystrophy in HIV-1 infected patients treated during primary infection”. AIDS 2001; 15: 282-284.

17. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. “Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors”. AIDS 1999; 13: F63-F70.

18. Hadigan C, Meigs JB, Wilson PW, et al. “Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution”. Clin Infect Dis 2003; 36:909.